Skip to main content
Log in

Effects of letrozole on bone biomarkers and femur fracture in female rats

  • Published:
Journal of Physiology and Biochemistry Aims and scope Submit manuscript

Abstract

We aimed to investigate the effects of the aromatase inhibitor letrozole on femur fracture and serum levels of alkaline phosphatase (ALP), calcium and phosphate in female rats. Intact 32 Sprague-Dawley female rats were divided into four groups (n=8): control, letrozole 0.2 , letrozole 1 (treatment of 0.2 and 1 mg/kg for six weeks) and recovery (letrozole-treated 1 mg/kg for six weeks then allowed to recover for two weeks). Besides, 24 ovariectomized rats were divided into three groups (n=8): ovariectomized+control, ovariectomized+letrozole and ovariectomized+letrozole+ estradiol (10 μg/rat). After experimental period, rats’ femur bones were removed for biomechanical studies following decapitation. Serum ALP, calcium and phosphate were measured. Biomechanical values, ALP and phosphate significantly increased by letrozole in a dose-dependent manner (p<0.05) while calcium levels and net bone area decreased (p<0.05). Ultimate strength was positively correlated with ALP and phosphate and negatively correlated with calcium. The results indicate that letrozole may increase risk of bone fracture and affect bone biomarkers such as ALP, calcium and phosphate in both intact and ovariectomized rats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ramaswamy B., Shapiro C.L. (2003) Osteopenia and osteoporosis in women with breast cancer.Semin Oncol,30, 763–75.

    Article  CAS  PubMed  Google Scholar 

  2. Garnero P., Sornay-Rendu E., Chapuy M.C., Delmas P.D. (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.J Bone Miner Res,11, 337–49.

    Article  CAS  PubMed  Google Scholar 

  3. Gelber R.D., Bonetti M., Castiglione-Gertsch M., Coates A.S., Goldhirsch A. (2003) Tailoring adjuvant treatments for the individual breast cancer patient.Breast,12, 558–68.

    Article  CAS  PubMed  Google Scholar 

  4. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston, R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Therasse P., Palmer M.J., Pater J.L. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.N Engl J Med,349, 1793–802.

    Article  CAS  PubMed  Google Scholar 

  5. Gail M.H., Costantino J.P., Bryant J., Croyle R., Freedman L., Helzlsouer K., Vogel V. (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.J Natl Cancer Inst,91, 1829–46.

    Article  CAS  PubMed  Google Scholar 

  6. Cole P.A., Robinson C.H. (1990) Mechanism and inhibition of cytochrome P-450 aromatase.J Med Chem,33, 2933–42.

    Article  CAS  PubMed  Google Scholar 

  7. Santen R.J., Manni A., English H.F., Heitjan D. (1990) Androgen-primed chemotherapy-experimental confirmation of efficacy.J Steroid Biochem Mol Biol,37, 1115–20.

    Article  CAS  PubMed  Google Scholar 

  8. Howell A., Buzdar A. (2005) Are aromatase inhibitors superior to antiestrogens?J Steroid Biochem Mol Biol,93, 237–47.

    Article  CAS  PubMed  Google Scholar 

  9. Osborne C., Tripathy D. (2005) Aromatase inhibitors: rationale and use in breast cancer.Annu Rev Med,56, 103–16.

    Article  CAS  PubMed  Google Scholar 

  10. Kilic-Okman T., Kucuk M., Altaner S. (2003) Comparison of the effects of letrozole and clomiphene citrate on ovarian follicles, endometrium, and hormone levels in the rat.Fertil Steril,80, 1330–2.

    Article  PubMed  Google Scholar 

  11. Pérez E.A., Weilbaecher K. (2006) Aromatase inhibitors and bone loss.Oncology (Williston Park),20, 1029–39; discussion 1039-40, 1042, 1048.

    Google Scholar 

  12. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Cameron D.A., Palmer M.J., Pater J.L. (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.J Natl Cancer Inst,97, 1262–71.

    Article  CAS  PubMed  Google Scholar 

  13. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., Hoctin-Boes G., Houghton J., Locker G.Y., Tobias J.S. (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer.Lancet,365, 60–2.

    Article  CAS  Google Scholar 

  14. Heshmati H.M., Khosla S., Robins S.P., O’Fallon W.M., Melton L.J., Riggs B.L. (2002) Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women.J Bone Miner Res,17, 172–8.

    Article  CAS  PubMed  Google Scholar 

  15. Gasser J.A., Green J.R., Shen V., Ingold P., Rebmann A., Bhatnagar A.S., Evans D.B. (2006) A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.Bone,39, 787–95.

    Article  CAS  PubMed  Google Scholar 

  16. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., Jones S.E., Alvarez I., Bertelli G., Ortmann O., Coates A.S., Bajetta E., Dodwell D., Coleman R.E., Fallowfield L.J., Mickiewicz E., Andersen J., Lonning P.E., Cocconi G., Stewart A., Stuart N., Snowdon C.F., Carpentieri M., Massimini G., Bliss J.M., van de Velde C. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.N Engl J Med,350, 1081–92.

    Article  CAS  PubMed  Google Scholar 

  17. Coates A.S., Keshaviah A., Thurlimann B., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Colleoni M., Lang I., Del Mastro L., Smith I., Chirgwin J., Nogaret J.M., Pienkowski T., Wardley A., Jakobsen E.H., Price K.N., Goldhirsch A. (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrineresponsive early breast cancer: update of study BIG 1–98.J Clin Oncol,25, 486–92.

    Article  CAS  PubMed  Google Scholar 

  18. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Rabaglio M., Smith I., Wardley A., Price K.N., Goldhirsch A. (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.N Engl J Med,353, 2747–57.

    Article  PubMed  Google Scholar 

  19. Pérez E.A., Josse R.G., Pritchard K.I., Ingle J.N., Martino S., Findlay B.P., Shenkier T.N., Tozer R.G., Palmer M.J., Shepherd L.E., Liu S., Tu D., Goss P.E. (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.J Clin Oncol,24, 3629–35.

    Article  PubMed  Google Scholar 

  20. Eastell R. (2007) Aromatase inhibitors and bone.J Steroid Biochem Mol Biol,106, 157–61.

    Article  CAS  PubMed  Google Scholar 

  21. Harper-Wynne C., Ross G., Sacks N., Salter J., Nasiri N., Iqbal J., A’Hern R., Dowsett M. (2002) Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.Cancer Epidemiol Biomarkers Prev,11, 614–21.

    CAS  PubMed  Google Scholar 

  22. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.J Clin Invest,111, 1221–30.

    CAS  PubMed  Google Scholar 

  23. Aydin M., Yilmaz B., Alcin E., Nedzvetsky V.S., Sahin Z., Tuzcu M. (2008) Effects of letrozole on hippocampal and cortical catecholaminergic neurotransmitter levels, neural cell adhesion molecule expression and spatial learning and memory in female rats.Neuroscience,151, 186–94.

    Article  CAS  PubMed  Google Scholar 

  24. Ross P.D., Kress B.C., Parson R.E., Wasnich R.D., Armour K.A., Mizrahi I.A. (2000) Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study.Osteoporos Int,11, 76–82.

    Article  CAS  PubMed  Google Scholar 

  25. National Osteoporosis Foundation InNational Osteoporosis Foundation: Physician’s Guide to Prevention and Treatment of Osteoporosis. (2003). Available at http: // www.nof.org Washington, DC.

  26. Kumru S., Yildiz A.A., Yilmaz B., Sandal S., Gurates B. (2007) Effects of aromatase inhibitors letrozole and anastrazole on bone metabolism and steroid hormone levels in intact female rats.Gynecol Endocrinol,23, 556–61.

    Article  CAS  PubMed  Google Scholar 

  27. Benito M., Gomberg B., Wehrli F.W., Weening R.H., Zemel B., Wright A.C., Song H.K., Cucchiara A., Snyder P.J. (2003) Deterioration of trabecular architecture in hypogonadal men.J Clin Endocrinol Metab,88, 1497–502.

    Article  CAS  PubMed  Google Scholar 

  28. Bagi C.M., Hanson N., Andresen C., Pero R., Lariviere R., Turner C.H., Laib A. (2006) The use of micro-CT to evaluate cortical bone geometry and strength in nude rats: correlation with mechanical testing, pQCT and DXA.Bone,38, 136–44.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Z. Yonden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yonden, Z., Aydin, M., Alcin, E. et al. Effects of letrozole on bone biomarkers and femur fracture in female rats. J Physiol Biochem 65, 267–275 (2009). https://doi.org/10.1007/BF03180579

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03180579

Keywords

Navigation